Fas and Fas-ligand expression in seminomatous testes

APMIS

Volumn 107, Issue 4, 1999, Pages 431-436

  Braendstrup O ^a   Bols, B ^b   Jensen, L ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

Fas; FasL; Seminoma; Sertoli cells

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; RETE TESTIS; SCORING SYSTEM; SEMINIFEROUS TUBULE; SEMINOMA; SERTOLI CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0013012553     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01577.x     Document Type: Article

References (30)

1. 1. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-55.
2. 2. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995;154:3806-13.
3. 3. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-4.
4. 4. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
5. 5. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
6. 6. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370:650-2.
7. 7. Dhein J, Walczak H, Bäumler C, Debatin K-M, Krammer PH. Autocrine T-cell suicide mediated by APO-1, Nature 1995;373:438-41.
8. 8. Lynch DH, Ramsdall F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995;16:569-74.
9. 9. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Ann Rev Immunol 1991;9:243-9.
10. 10. Russell JH, Wang R, Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells. Eur J Immunol 1993;23:379-82.
11. 11. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994;76: 969-76.
12. 12. Fisher GH, Rosenberg FJ, Strauss SE, Dale JK, Middelton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
13. 13. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
14. 14. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133:335-43.
15. 15. Lee J, Richburg JH, Younkin SC, Boekelheide K. The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 1997;138: 2081-8.
16. 16. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
17. 17. Sugihara A, Saiki S, Tsuji M, Tsujimura T, Nakata Y, Kubota A, et al. Expression of Fas and Fas ligand in testes and testicular germ cell tumors: an immunohistochemical study. Anticancer Res 1997;17:3861-6.
18. 18. Bell DA, Flotte TJ, Bhan AK. Immunohistochemical characterization of seminoma and its inflammatory infiltrate. Hum Pathol 1987;18: 511-20.
19. 19. Brændstrup O. HLA class I antigens are expressed by Sertoli cells of intratubular germ cell neoplasia. APMIS 1996;104:579-82.
20. 20. Nouri AME, Hussain RF, Oliver RTD, Handy AM, Bartkova I, Bodmer JG. Immunological paradox in testicular tumours: the presence of a large number of activated T-cells despite the complete absence of MHC antigens. Eur J Cancer 1993;13:1895-9.
21. 21. Kradin RL, Bhan AK, Tumor infiltrating lymphocytes. Lab Invest 1993;69:635-8.
22. 22. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977;25:1-54.
23. 23. Lau HT, Yu M, Fontana A, Stoeckert Jr CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-12.
24. 24. Haas GG, D'Cruz OJ, De Bault LE. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol 1988;18:47-51.
25. 25. Kuhlmann D, Dohr G, Pusch HH, Scherbaum W, Schieferstein G, Uchanska-Ziegler B, et al. Absence of HLA class I and class II antigens as well as beta2-microglobulin from normal and pathological spermatozoa. Tissue Antigens 1986; 7:179-84.
26. 26. Pöllänen P, Niemi M. Immunohistochemical identification of macrophages, lymphoid cells and HLA antigens in the human testis. Int J Androl 1987;10:37-40.
27. 27. Brændstrup O, Jensen L, Werdelin O. Sertoli cells, but not tumor cells, of seminoma in situ express ICAM-1. APMIS 1996;104:817-22.
28. 28. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(APO-1/CD95) ligand: implications for tumor immune escape. Science 1996; 2274:1363-6.
29. 29. Walker PR, Saas P, Dietrich P-Y. Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J Immunol 1997;158:4521-4.
30. 30. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;68:415-29.